^
Association details:
| Biomarker: | ARID1A deletion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | berzosertib (M6620) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Excerpt:
We next assessed whether the clinical ATRi, VX-970, could inhibit ARID1A-deficient tumours in vivo. To do this, we generated cohorts of mice with established xenograft tumours derived from either HCT116 ARID1A+/+ or ARID1A−/− cells...We found that, compared with vehicle treatment, VX-970 had no effect on ARID1A+/+ tumours (P=0.45, ANOVA, Fig. 3b) but significantly inhibited the growth of ARID1A−/− tumours (P=0.024, ANOVA, Fig. 3b).
DOI:
10.1038/ncomms13837
